<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01140204</url>
  </required_header>
  <id_info>
    <org_study_id>1-325-02</org_study_id>
    <nct_id>NCT01140204</nct_id>
  </id_info>
  <brief_title>Short-Term Exposure to Lipophilic Anti-proliferative Drugs Delivered by Angiographic Contrast Media</brief_title>
  <official_title>Restenosis Inhibition by Short-Term Exposure to Lipophilic Anti-proliferative Drugs Delivered by Angiographic Contrast Media</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized, placebo-controlled, multi-centre study, double-blind within each dose
      level, with four ascending dose levels to test the tolerability and safety of
      iopromide-paclitaxel in patients with de novo lesions in coronary arteries. Thirty-two
      patients were included into the trial, which were divided into four treatment groups. A total
      of four concentration levels of paclitaxel-iopromide concentrations were investigated. In
      each treatment group, six patients received iopromide-paclitaxel and two patients placebo
      (iopromide without paclitaxel). In each patient, the doses were adjusted individually as
      needed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Non-stent-based immediate release formulations of paclitaxel have been shown to
      reduce in-stent restenosis in animal experiments and initial clinical trials. Paclitaxel
      dissolved in the angiographic contrast agent iopromide was well tolerated and inhibited
      neointimal proliferation in a dose-dependent manner after injection into porcine coronary
      arteries.

      Methods: As a first step in entering clinical development, a phase I trial was performed
      using 4 ascending paclitaxel dose/concentration levels: samples of up to 100 ml of the
      contrast agent containing 10, 50, 100 or 200 μM paclitaxel were randomly administered to 6
      adult patients each assigned to bare metal stent implantation for single de novo coronary
      artery lesions, while 8 patients treated with plain contrast medium served as controls.
      Safety variables and tolerability as well as angiographic parameters were assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of intracoronary application</measure>
    <time_frame>ca. 30 minutes (during intervention)</time_frame>
    <description>Continuous monitoring electrocardiogram (ECG)
Vital signs
Invasive measure of blood pressure
Lab variables: red blood count, white blood count, diff, creatinine kinase, creatinine kinase - muscle bound, creatinine
Cmax of paclitaxel in serum
12-lead ECG
Adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late lumen loss</measure>
    <time_frame>6 months</time_frame>
    <description>Difference between angiographic in-stent minimum lumen diameter at 6 months follow-up and post-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis rate</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as a diameter stenosis of ≥50% (assessed by quantitative coronary angiography) at any control angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined clinical endpoints (Major adverse cardiac events, MACE)</measure>
    <time_frame>6 months</time_frame>
    <description>Abrupt and sub-abrupt closure
Target lesion revascularization
Myocardial infarction
Death</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Contrast medium without Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iopromide Paclitaxel 0.85 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iopromide Paclitaxel 0.85 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iopromide Paclitaxel 4.27 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iopromide Paclitaxel 4.27 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iopromide Paclitaxel 8.54 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iopromide Paclitaxel 8.54 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iopromide Paclitaxel 17.08 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iopromide Paclitaxel 17.08 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of a bare metal stent</intervention_name>
    <description>Bare Metal Stent</description>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_label>Iopromide Paclitaxel 0.85 mg</arm_group_label>
    <arm_group_label>Iopromide Paclitaxel 4.27 mg</arm_group_label>
    <arm_group_label>Iopromide Paclitaxel 8.54 mg</arm_group_label>
    <arm_group_label>Iopromide Paclitaxel 17.08 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and postmenopausal female patients

          -  aged 18 years and older

          -  clinical evidence of stable or unstable angina, a positive functional test and a
             stentable de novo lesion in a native coronary artery

          -  diameter stenosis &gt; 70% (visual estimate), lesion length &lt; 25 mm, and a vessel
             diameter ≥ 2.5 mm.

        Exclusion Criteria:

          -  acute myocardial infarction

          -  left ventricular ejection fraction of &lt; 30%

          -  aorto-ostial lesion

          -  unprotected left main lesion or a bypass graft

          -  clear angiographic calcification in the target lesion

          -  visible thrombus proximal to the lesion

          -  chronic total occlusion

          -  platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3

          -  WBC &lt;3,000 cells/mm3

          -  known hypersensitivity or contraindication to aspirin, heparin, clopidogrel,
             abciximab, paclitaxel, stainless steel

          -  sensitivity to contrast media not amenable to adequate premedication

          -  medical illness (i.e. cancer, liver disease or congestive heart failure) associated
             with a life expectancy of less than two years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Scheller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Saarland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Rutsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite Hospital, Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Saarland</name>
      <address>
        <city>Homburg/Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite University Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2010</study_first_submitted>
  <study_first_submitted_qc>June 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2010</study_first_posted>
  <last_update_submitted>June 8, 2010</last_update_submitted>
  <last_update_submitted_qc>June 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bruno Scheller, MD</name_title>
    <organization>University Hospital, Saarland</organization>
  </responsible_party>
  <keyword>stent</keyword>
  <keyword>contrast media</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>stent implantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

